
Opinion|Videos|December 14, 2023
A Patient’s Experience With Initial Treatment for RCC
Author(s)Thomas E. Hutson, DO, PharmD, Kacie Ellis, RN
Mr. Fuentes felt it was important to understand the range of potential side effects to anticipate how his body would potentially react to treatment for RCC and determine his physical abilities and support needs, but was most focused on whether his first post-treatment scan showed tumor shrinkage.
Advertisement
Episodes in this series

Advertisement
Related to this article

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape
2
Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC
3
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
4
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
5


